Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction

• DOI: 10.1002/ehf2.13683
• Publication Date: 2021-11-03T09:19:50Z
• Authors: Mitsutaka Nakashima; Toru Miyoshi; Kentaro Ejiri; Hajime Kihara; Yoshiki Hata; Toshihiko Nagano; Atsushi Takaishi; Hironobu Toda; Seiji Nanba; Yoichi Nakamura; Satoshi Akagi; Satoru Sakuragi; Taro Minagawa; Yusuke Kawai; Nobuhiro Nishii; Soichiro Fuke; Masaki Yoshikawa; Kazufumi Nakamura; Hiroshi Ito
• Keywords: Heart Failure; Sodium glucose co‐transporter 2 inhibitors; 610; 600; Stroke Volume; Original Articles; 3. Good health; 03 medical and health sciences; Heart failure with preserved ejection fraction; 0302 clinical medicine; Diabetes Mellitus, Type 2; Estimated plasma volume; RC666-701; Voglibose; Diseases of the circulatory (Cardiovascular) system; Humans; Sorbitol; Luseogliflozin; Prospective Studies; Plasma Volume; Sodium glucose co-transporter 2 inhibitors

Sodium glucose co-transporter 2 inhibitors have diuretic effects in both patients with glycosuria and natriuresis. We sought to assess the effect of luseogliflozin on estimated plasma volume (ePV) type diabetes heart failure preserved ejection fraction (HFpEF).